Nonprofit’s petition aims to expedite Canadian access to Rezdiffra
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Fatty liver disease
Dosing begins in Phase 2 trial of DD01 in treating fatty liver disease
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of two forms of fatty…
Efruxifermin Phase 3 trials now enrolling fatty liver disease patients
Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated…
Two Phase 3 pegozafermin trials for severe fatty liver disease enrolling
Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty liver disease, are enrolling participants,…
Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…
Poor sleep quality ID’d as key risk factor for fatty liver disease
Poor sleep quality — noted by researchers as increasingly common in modern society — is significantly linked to a higher chance of having metabolic dysfunction-associated…
American Liver Foundation aiming to improve care for patients
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
Facial temperature patterns could help detect MASLD: Study
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be detectable using computer-based analyses of…
Ferroptosis, type of cell death, may be therapeutic target for MASLD
A type of cell death called ferroptosis contributes to metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease that occurs more…
Targeting SEMA3A protein could help slow MASLD: Study
A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate in the livers of people…
